Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

K Goto; I Sekine; Y Nishiwaki; R Kakinuma; K Kubota; T Matsumoto; H Ohmatsu; S Niho; T Kodama; T Shinkai

doi:10.1038/sj.bjc.6602056

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

Identifier:nobleid.org/w1/20260515/D507DF67

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D507DF67.svg?ark=w1%2F20260515%2FD507DF67)](https://nobleid.org/work/w1/20260515/D507DF67)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

Identifier:nobleid.org/w1/20260515/D507DF67

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D507DF67.svg?ark=w1%2F20260515%2FD507DF67)](https://nobleid.org/work/w1/20260515/D507DF67)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work